Search - tctmd.com

Displaying 1 - 20 of 51

Sort: Relevancy | Date

POLY-HF: Polypill Pays Dividends in Patients With HFrEF

News Conference News AHA 2025

POLY-HF: Polypill Pays Dividends in Patients With HFrEF

November 14, 2025

Vericiguat Misses Mark in Stable, Well-Treated HFrEF Patients: VICTOR

News Conference News ESC 2025

Vericiguat Misses Mark in Stable, Well-Treated HFrEF Patients: VICTOR

Michael O'Riordan

August 31, 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

News Conference News ESC 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

Michael O'Riordan

August 30, 2025

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

News Conference News ACC 2025

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

Michael O'Riordan

April 01, 2025

REALIZE-K: Potassium Binder Boosts MRA Use in Hyperkalemic HFrEF Patients

News Conference News AHA 2024

REALIZE-K: Potassium Binder Boosts MRA Use in Hyperkalemic HFrEF Patients

November 22, 2024

Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression

News Conference News AHA 2024

Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression

Yael L. Maxwell

November 20, 2024

Nasal Bumetanide Safe, Effective in Healthy Adults

News Conference News AHA 2024

Nasal Bumetanide Safe, Effective in Healthy Adults

Yael L. Maxwell

November 18, 2024

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

News Conference News AHA 2024

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

November 17, 2024

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

News Conference News AHA 2024

Audits and Feedback Aid Pharmacist-Driven HF Care: PHARM-HF A&F

Michael O'Riordan

November 16, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

News Conference News HFSA 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

October 02, 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

News Conference News HFSA 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Michael O'Riordan

October 02, 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

News Conference News ESC Heart Failure 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

Durable 1-Year Outcomes With Coronary Sinus Shunt for HF: ALT-FLOW EFS

News Conference News THT 2024

Durable 1-Year Outcomes With Coronary Sinus Shunt for HF: ALT-FLOW EFS

Michael O'Riordan

March 06, 2024

Seeing Sticker Price for HFrEF Meds Opens Door to Discussions

News Conference News AHA 2023

Seeing Sticker Price for HFrEF Meds Opens Door to Discussions

November 14, 2023

Dropping Aspirin Cuts Strokes, Bleeds, Hospital Stays in LVAD Patients: ARIES-HCM3

News Conference News AHA 2023

Dropping Aspirin Cuts Strokes, Bleeds, Hospital Stays in LVAD Patients: ARIES-HM3

November 11, 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

November 11, 2023

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

News Conference News ESC 2023

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

August 30, 2023

IV Iron in HF Misses (Again) in HEART-FID, but Meta-analysis Sees a Role

News Conference News ESC 2023

IV Iron in HF Misses (Again) in HEART-FID, but Meta-analysis Sees a Role

August 26, 2023

SGLT2i Still Underprescribed in HFrEF, New US Analysis Confirms

News Conference News ESC Heart Failure 2023

SGLT2i Still Underprescribed in HFrEF, New US Analysis Confirms

June 06, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.